Roche’s Genentech inks deal with Sosei Heptares
Under the terms of the agreement, Sosei Heptares is eligible to receive US$26 million in upfront and near-term payments.
Read More
Tag: Sosei
Sosei Heptares to get $3m Pfizer milestone payment
The deal was initially signed in November 2015 to research and develop potential new medicines directed at up to ten GPCR targets across multiple therapeutic areas.
Read More
Sosei get $2.5m for QVM149 MAA
The company recently announced positive data from two Phase II clinical studies, in which QVM149 was shown to be superior to the comparators.
Read More
Sosei doses first patient with experimental neurodegenerative drug
Sosei has announced that the first healthy subject has been dosed with HTL0014242 – a novel small molecule being tested for its ability to slow neurodegeneration.
Read More
Allergan, Sosei suspend clinical development of dementia drug
Allergan and Sosei are voluntarily suspending clinical development activities with HTL0018318 pending investigation of an unexpected toxicology finding in an animal study involving non-human primates.
Read More
Heptares, ICL sign gastrointestinal R&D pact
Heptares Therapeutics, the UK-headquartered wholly-owned subsidiary of Japan’s Sosei Group, has formed a new drug research and development pact with Imperial College London focused on gastrointestinal disease.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
